Top 5 Low Price Stocks To Own Right Now

Small SUVs are the hottest segment in the new car market right now. So maybe it shouldn’t be surprising that a big chunk of the new vehicle unveilings at the Los Angeles Auto Show were little crossover SUVs.

It seemed like there was an SUV popping out every time you turned around. For starters, Ford unveiled its new EcoSport just before the show with DJ Khaled doing the honors.

The Jeep Compass is another example of the car market’s madness for small-sized SUVs. The current version is a strong seller despite abysmal reviews. Consumer Reports gave it the lowest rating of any compact SUV and Car & Driver awarded it a mere 1.5 out of a possible five stars.

And yet, as of last month, Jeep Compass sales for the year were up 44%. According to Fiat Chrysler Automobiles (FCAM), which makes Jeeps, the sales jump reflects the Compass’s relatively low price given all the desirable SUV features that it offers.

DJ Khaled unveils new Ford EcoSport on Snapchat

It’s too soon to know, of course, how good the new Compass is but it should at least be a vast improvement over the outgoing model. Since it’s a Jeep, engineers took off-road capability seriously in creating the new Compass. Two different full-time all-wheel-drive systems are available including a super-slow off-road “crawl” gearing ratio. “Trail Rated” versions can wade through 19 inches of water and climb over steep hills and out of tight ditches. At the same time, Jeep also promises better on-road behavior.

Top 5 Low Price Stocks To Own Right Now: Stage Stores, Inc.(SSI)

Advisors’ Opinion:

  • [By Paul Ausick]

    Stage Stores Inc. (NYSE: SSI) dropped nearly 20% on Monday to post a new 52-week low of $3.21 after closing at $4.00 on Friday. Volume was more than 5 times the daily average of about 650,000 shares. The company posted poor holiday season sales last Friday and lowered its guidance.

  • [By Lisa Levin]

    Stage Stores Inc (NYSE: SSI) was down, falling around 16 percent to $3.35 as the company reported a drop in its holiday season same-store sales and lowered its earnings guidance. The retailer’s same-store sales dropped 7.3 percent for the nine-week period ending December 31, 2016.

Top 5 Low Price Stocks To Own Right Now: Seanergy Maritime Holdings Corp(SHIP)

Advisors’ Opinion:

  • [By Elizabeth Balboa]

    Meanwhile, Safe Bulkers, Inc. (NYSE: SB) rose $0.73 throughout the 2016, Seanergy Maritime Holdings Corp. (NASDAQ: SHIP) fell $1.69 and Navios Maritime Partners L.P. (NYSE: NMM) dropped $0.93.

  • [By Paul Ausick]

    Seanergy Maritime Holdings Corp. (NASDAQ: SHIP) dropped 50% on Thursday to post a new 52-week low of $1.10 after closing at $2.20 on Wednesday. The stock’s 52-week high is $8.65. Volume approaching 13 million shares was nearly 15 times the daily average of 850,000. The dry bulk carrier company priced a secondary offering of 10 million shares and warrants at $1.50 per share this morning.

Top 5 Low Price Stocks To Own Right Now: Clean Diesel Technologies Inc.(CDTI)

Advisors’ Opinion:

  • [By Monica Gerson]

    Clean Diesel Technologies, Inc. (NASDAQ: CDTI) is projected to post a quarterly loss at $0.18 per share on revenue of $10.25 million.

    Sphere 3D Corp. (NASDAQ: ANY) is estimated to post a quarterly loss at $0.11 per share on revenue of $22.10 million.

Top 5 Low Price Stocks To Own Right Now: Opexa Therapeutics, Inc.(OPXA)

Advisors’ Opinion:

  • [By Elizabeth Balboa]

    Opexa Therapeutics Inc (NASDAQ: OPXA) and Acer Therapeutics announced a merger that will result in 11.2-percent ownership by current Opexa shareholders and 88.8-percent ownership by current Acer shareholders.

  • [By Lisa Levin]

    Opexa Therapeutics Inc (NASDAQ: OPXA) shares dropped 70 percent to $1.02 after the company disclosed that its top-line results from Phase 2b Abili-T trial evaluating Tcelna did not meet primary endpoint.

  • [By Lisa Levin]

    Opexa Therapeutics Inc (NASDAQ: OPXA) shares were also up, gaining 66 percent to $1.08 after the company announced plans to acquire Acer Therapeutics.

Top 5 Low Price Stocks To Own Right Now: Medtronic plc(MDT)

Advisors’ Opinion:

  • [By James E. Brumley]

    When an investor thinks of stocks in the cardio-monitoring arena, names like General Electric Company (NYSE:GE) and Medtronic PLC (NYSE:MDT) tend to surface first. And well they should. Medtronic is the largest name dedicated solely to equipment that tells doctors and nurses how well a patient’s heart is functioning, while GE Healthcare smartly leverages the name of its parent company’s recognizable name to win market share in the medical equipment space.

    General Electric and Medtronic aren’t the only names in town, however, and certainly not the top prospects for an investor seeking out a fresh, undiscovered growth opportunity. That honor arguably belongs to an up-and-coming small cap outfit called Biotricity Inc. (OTCMKTS:BTCY), which is nearing its first-ever revenue.

    Don’t look for a Biotricity product quite yet, as they’re not on the market. Consumers as well as investors will want to keep their eyes and ears open for two of them soon though, however, with one of those devices being a high-precision, FDA-approved instrument for use by healthcare workers in a clinical setting. The other device is a consumer-oriented version of the same technology, giving BTCY access to not just one but two crucial markets. Even more recently Biotricity reported it was opening up its development pipeline to the fetal monitoring and sleep apnea markets. Heart-monitoring is the near-term venture, though.

    The two products are called biotricity and biolife (neither moniker is supposed to be capitalized). The latter is a wireless, remote consumer-oriented heart rate and activity monitoring device, and the former is a clinical-grade monitoring device… also wireless and remotely operated/monitored.

    Bioflux is only available by prescription. The bioflux hardware includes an ECG (heart-rhythm) monitoring device, software, and if desired, service from a monitoring lab that performs remote diagnostic monitoring for up to 30 consecutive days at a time. It

  • [By Todd Campbell]

    At Medtronic (NYSE:MDT), one of the country’s largest medical-device companies, these sensors are even attached to an insulin pump patients wear that canautomatically administer insulin as it’s needed.

  • [By Ben Levisohn]

    US sequential acceleration returns to the prior curve and debunks the bear case. Sequential growth in US [transcatheter aortic valve replacement, or TAVR,] in 1Q17 was ~12%, more in line with the ~13.5% average growth rate seen in the five quarters leading up to 3Q16. It’s hard to pinpoint the drivers, but we see several dynamics, including: (i) underlying device utilization thus far in 1Q, (ii) faster ramp at new hospitals where one additional TAVR per center is worth $15mn (~65% of the US upside we saw this quarter), and (iii) less acute competitive pressure from Medtronic (MDT) on larger valve sizes. SURTAVI likely played a limited role but management did not rule it out. Guidance implies a more conservative q/q US growth of ~3% for the rest of the year vs the ~12% this quarter, but underlying strength in the quarter is a material shift in US growth and intermediate penetration. As we stated in our preview, we favored the risk reward into the quarter given achieva ble expectations and the >20 point lag vs Intuitive YTD and would expect significant recovery tomorrow. Momentum likely continues into 2Q17 as signs of improving intermediate risk penetration provide important offsets to increased competition from Boston in early-2018 before mitral takes hold.

  • [By Ben Levisohn]

    Medtronic (MDT) has risen 1.9% to $81.75 on reports that Cardinal Health (CAH) will buy its medical supplies business.

    Jazz Pharmaceuticals (JAZZ) has jumped 6.3% to $149.45 after settling a patent dispute.

  • [By Matthew Briar]

    What do you get when you combine a medical device company like Medtronic plc (NYSE:MDT) and a mobile communication device like the iPhone from Apple Inc. (NASDAQ:AAPL)? You get a CardioComm Solutions Inc. (OTCMKTS:EKGGF, CVE:EKG), which can turn your smartphone into a high-powered, high-functioning heart-monitoring piece of hardware as potent as anything you’d have access to in the hospital.

    Yes, there’s a market for the melding of what Apple and Medtronic — and several other players — do. The healthcare wearable market was worth $5.1 billion in 2015, and now that such technologies are being accepted, its revenues could reach $19 billion by 2020. Meanwhile, the heart-monitoring space happens to be a market worth more than $20 billion per year, and some say it will be worth $26.7 billion by 2020. CardioComm Solutions is nestled nicely between the two of them.

    CardioComm Solutions is the name behind a brand of wellness products sold under the HeartCheck monikor. Those devices are small, handheld portable ECG (electrocardiogram) readers that put the power of a doctor’s or hospital’s heart-monitoring hardware in the hands of individuals who can use them just as effectively.

    Its flagship products are the HeartCheck ECG Pen, for consumers (available without a prescription), and the HeartCheck ECG monitoring device (available only by prescription) that’s a higher-level technology. More are on the way too. The ECG ‘Card’ is a credit-card sized device that syncs up with — and is powered by — a smartphone in close proximity. Also on the way is the HeartCheck band, which is worn on the wrist. It does a lot that the Fitbit bands do, with the added benefit of being able to produce clinical-grade ECG readouts viewable not just by the user, but by a doctor, clinic, or call center if that user chooses to deliver them remotely using the company’s platform.

    Bolstering the value proposition is the fact that all of its wares are — or will be

  • [By Ben Levisohn]

    Cardinal Health (CAH) tumbled to the bottom of the S&P 500 today after agreeing to buy Medtronic’s (MDT) medical supplies business for $6.1 billion and offering disappointing guidance.

Leave a Reply

Your email address will not be published. Required fields are marked *